Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 8.73% from its latest closing price compared to the recent 1-year high of $36.36. The company’s stock price has collected 14.68% of gains in the last five trading sessions. The Wall Street Journal reported on 02/09/21 that SoftBank Makes $900 Million Bet on Biotech Star
Is It Worth Investing in Pacific Biosciences of California Inc. (NASDAQ :PACB) Right Now?
Plus, the 36-month beta value for PACB is at 1.55. Opinions of the stock are interesting as 3 analysts out of 6 who provided ratings for Pacific Biosciences of California Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $16.17, which is $10.79 above the current price. PACB currently public float of 204.82M and currently shorts hold a 16.78% ratio of that float. Today, the average trading volume of PACB was 7.16M shares.
PACB’s Market Performance
PACB stocks went up by 14.68% for the week, with a monthly drop of -17.68% and a quarterly performance of -53.62%, while its annual performance rate touched -84.50%. The volatility ratio for the week stands at 8.44% while the volatility levels for the past 30 days are set at 9.14% for Pacific Biosciences of California Inc. The simple moving average for the period of the last 20 days is -7.08% for PACB stocks with a simple moving average of -70.79% for the last 200 days.
Analysts’ Opinion of PACB
Many brokerage firms have already submitted their reports for PACB stocks, with Cantor Fitzgerald repeating the rating for PACB by listing it as a “Overweight.” The predicted price for PACB in the upcoming period, according to Cantor Fitzgerald is $31 based on the research report published on January 21st of the current year 2022.
Piper Sandler, on the other hand, stated in their research note that they expect to see PACB reach a price target of $20. The rating they have provided for PACB stocks is “Neutral” according to the report published on January 06th, 2022.
Cowen gave a rating of “Market Perform” to PACB, setting the target price at $30 in the report published on October 15th of the previous year.
PACB Trading at -22.87% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.32% of loss for the given period.
Volatility was left at 9.14%, however, over the last 30 days, the volatility rate increased by 8.44%, as shares sank -17.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.43% lower at present.
During the last 5 trading sessions, PACB rose by +14.68%, which changed the moving average for the period of 200-days by -85.36% in comparison to the 20-day moving average, which settled at $4.91. In addition, Pacific Biosciences of California Inc. saw -77.47% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at PACB starting from Farmer Michele, who sale 3,573 shares at the price of $5.55 back on May 18. After this action, Farmer Michele now owns 60,354 shares of Pacific Biosciences of California Inc., valued at $19,819 using the latest closing price.
Kim Susan G., the Chief Financial Officer of Pacific Biosciences of California Inc., sale 1,062 shares at $11.06 during a trade that took place back on Feb 17, which means that Kim Susan G. is holding 134,966 shares at $11,746 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -136.51 for the present operating margin
- +45.04 for the gross margin
The net margin for Pacific Biosciences of California Inc. stands at -138.85. Equity return is now at value -26.70, with -9.70 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 15.35.